These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 35394529)
1. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954 [TBL] [Abstract][Full Text] [Related]
3. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC Front Immunol; 2022; 13():920333. PubMed ID: 35865529 [TBL] [Abstract][Full Text] [Related]
4. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection? Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Alexander JL; Kennedy NA; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Liu Z; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Goodhand JR; Hart AL; Lees CW; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):342-352. PubMed ID: 35123676 [TBL] [Abstract][Full Text] [Related]
6. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043 [TBL] [Abstract][Full Text] [Related]
7. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany. Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480 [TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919 [TBL] [Abstract][Full Text] [Related]
9. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease. Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z Front Immunol; 2023; 14():1257072. PubMed ID: 37965328 [TBL] [Abstract][Full Text] [Related]
10. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]. Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770 [TBL] [Abstract][Full Text] [Related]
11. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899 [TBL] [Abstract][Full Text] [Related]
12. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease. Dailey J; Kozhaya L; Dogan M; Hopkins D; Lapin B; Herbst K; Brimacombe M; Grandonico K; Karabacak F; Schreiber J; Liang BT; Salazar JC; Unutmaz D; Hyams JS Inflamm Bowel Dis; 2022 Jul; 28(7):1019-1026. PubMed ID: 34528661 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease. Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U Front Immunol; 2022; 13():889138. PubMed ID: 35634285 [TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type. Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656 [TBL] [Abstract][Full Text] [Related]
16. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease. Brenner EJ; Weaver KN; Zhang X; Kastl AJ; Strople JA; Adler J; Dubinsky MC; Bousvaros A; Watkins R; Dai X; Chen W; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Chun KY; Zikry M; Bastidas M; Firestine A; Craig RG; Boccieri ME; Long MD; Kappelman MD Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1475-1486.e4. PubMed ID: 38369224 [TBL] [Abstract][Full Text] [Related]
17. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study). Casas Deza D; Julián Gomara AB; Caudevilla Biota E; Beltrán B; Domènech E; Gutiérrez Casbas A; Mañosa M; Zabana Y; Roc Alfaro L; Valverde Romero E; García González E; Sicilia B; Laredo V; Alcalá Escriche MJ; Madero Velázquez L; Ferreiro-Iglesias R; Palmero Pérez A; Calafat M; Rubio Iturria S; Moraleja Yudego I; Ber Nieto Y; García Mateo S; Gisbert JP; Vicente Lidón R; Arias L; Alfambra E; Doñate Borao AB; Peña González E; Corsino Roche P; Vicuña Arregui M; Elorza A; Domínguez Cajal M; Chaparro M; Barreiro-de Acosta M; García-López S Gastroenterol Hepatol; 2024 Oct; 47(8):821-833. PubMed ID: 38007154 [TBL] [Abstract][Full Text] [Related]
18. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease. Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745 [TBL] [Abstract][Full Text] [Related]
19. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565 [TBL] [Abstract][Full Text] [Related]
20. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study). Casas Deza D; Julián Gomara AB; Caudevilla Biota E; Beltrán B; Domènech E; Gutiérrez Casbas A; Mañosa M; Zabana Y; Roc Alfaro L; Valverde Romero E; García González E; Sicilia B; Laredo V; Alcalá Escriche MJ; Madero Velázquez L; Ferreiro-Iglesias R; Palmero Pérez A; Calafat M; Rubio Iturria S; Moraleja Yudego I; Ber Nieto Y; García Mateo S; Gisbert JP; Vicente Lidón R; Arias L; Alfambra E; Doñate Borao AB; Peña González E; Corsino Roche P; Vicuña Arregui M; Elorza A; Domínguez Cajal M; Chaparro M; Barreiro-de Acosta M; García-López S Gastroenterol Hepatol; 2024; 47(7):750-758. PubMed ID: 38219960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]